Free Trial
→ Your book is inside (From Profits Run) (Ad)tc pixel Free BBOT Stock Alerts

BridgeBio Oncology Therapeutics (BBOT) Competitors

BridgeBio Oncology Therapeutics logo
$3.50 -0.10 (-2.78%)
Closing price 04:00 PM Eastern
Extended Trading
$3.63 +0.13 (+3.66%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BBOT vs. REPL, MNKD, TYRA, TRAX, and BCAX

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? BridgeBio Oncology Therapeutics's main competitors and comparable companies include Replimune Group (REPL), MannKind (MNKD), Tyra Biosciences (TYRA), First Tracks Biotherapeutics (TRAX), and Bicara Therapeutics (BCAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BridgeBio Oncology Therapeutics compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Replimune Group had 12 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 14 mentions for Replimune Group and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.42 beat Replimune Group's score of 0.32 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Replimune Group
3 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Replimune Group is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Replimune GroupN/AN/A-$313.94M-$3.15N/A
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.76N/A

Replimune Group has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market.

Replimune Group presently has a consensus price target of $12.00, suggesting a potential downside of 8.75%. BridgeBio Oncology Therapeutics has a consensus price target of $22.88, suggesting a potential upside of 535.42%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Replimune Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Replimune Group
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.60
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Replimune Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Replimune GroupN/A -159.32% -90.84%
BridgeBio Oncology Therapeutics N/A -46.90%-42.17%

Summary

BridgeBio Oncology Therapeutics beats Replimune Group on 10 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to MannKind?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

BridgeBio Oncology Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, MannKind has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

MannKind has higher revenue and earnings than BridgeBio Oncology Therapeutics. MannKind is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.76N/A
MannKind$348.97M3.52$5.86M-$0.13N/A

BridgeBio Oncology Therapeutics currently has a consensus price target of $22.88, indicating a potential upside of 535.42%. MannKind has a consensus price target of $8.34, indicating a potential upside of 118.42%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than MannKind.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
MannKind
2 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.50

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 2.6% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -46.90% -42.17%
MannKind -11.08%N/A -6.31%

In the previous week, MannKind had 4 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 6 mentions for MannKind and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.42 beat MannKind's score of 0.48 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MannKind
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BridgeBio Oncology Therapeutics beats MannKind on 8 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Tyra Biosciences?

Tyra Biosciences (NASDAQ:TYRA) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Tyra Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, BridgeBio Oncology Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Tyra Biosciences' return on equity of -46.39% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tyra BiosciencesN/A -46.39% -43.07%
BridgeBio Oncology Therapeutics N/A -46.90%-42.17%

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by company insiders. Comparatively, 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tyra Biosciences currently has a consensus target price of $46.89, indicating a potential upside of 124.03%. BridgeBio Oncology Therapeutics has a consensus target price of $22.88, indicating a potential upside of 535.42%. Given BridgeBio Oncology Therapeutics' higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Tyra Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Tyra Biosciences had 1 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 3 mentions for Tyra Biosciences and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.42 beat Tyra Biosciences' score of 0.13 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tyra Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tyra Biosciences is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyra BiosciencesN/AN/A-$119.95M-$2.40N/A
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.76N/A

Summary

Tyra Biosciences beats BridgeBio Oncology Therapeutics on 9 of the 14 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to First Tracks Biotherapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, First Tracks Biotherapeutics had 4 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 6 mentions for First Tracks Biotherapeutics and 2 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.42 beat First Tracks Biotherapeutics' score of 0.58 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
First Tracks Biotherapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.76N/A
First Tracks BiotherapeuticsN/AN/AN/A-$1.84N/A

BridgeBio Oncology Therapeutics currently has a consensus price target of $22.88, indicating a potential upside of 535.42%. First Tracks Biotherapeutics has a consensus price target of $65.17, indicating a potential upside of 97.53%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than First Tracks Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
First Tracks Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.79

First Tracks Biotherapeutics' return on equity of 0.00% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -46.90% -42.17%
First Tracks Biotherapeutics N/A N/A N/A

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BridgeBio Oncology Therapeutics beats First Tracks Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Bicara Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

BridgeBio Oncology Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.7, meaning that its share price is 170% less volatile than the broader market.

Bicara Therapeutics' return on equity of -41.49% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A -46.90% -42.17%
Bicara Therapeutics N/A -41.49%-38.59%

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 2 mentions for BridgeBio Oncology Therapeutics and 1 mentions for Bicara Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 1.42 beat Bicara Therapeutics' score of 0.00 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bicara Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

BridgeBio Oncology Therapeutics presently has a consensus target price of $22.88, suggesting a potential upside of 535.42%. Bicara Therapeutics has a consensus target price of $32.64, suggesting a potential upside of 88.76%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Bicara Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Bicara Therapeutics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.75

Bicara Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.76N/A
Bicara TherapeuticsN/AN/A-$137.95M-$3.10N/A

Summary

BridgeBio Oncology Therapeutics beats Bicara Therapeutics on 10 of the 13 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBOT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBOT vs. The Competition

Export
MetricBridgeBio Oncology TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$280.61M$3.81B$7.10B$13.40B
Dividend YieldN/A3.65%2.54%17.38%
P/E Ratio-1.2713.29273.9626.22
Price / SalesN/A1,289.01634.66101.27
Price / CashN/A39.0427.2234.74
Price / Book0.6816.7811.096.35
Net Income-$134.04M-$23.16M$3.49B$381.26M
7 Day Performance-10.71%-4.05%-2.30%-0.61%
1 Month Performance-61.02%-12.06%-7.05%-4.84%
1 Year PerformanceN/A14.68%5.65%1.12%

BridgeBio Oncology Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBOT
BridgeBio Oncology Therapeutics
4.1085 of 5 stars		$3.50
-2.8%		$22.88
+553.6%		N/A$280.61MN/AN/A88
REPL
Replimune Group
1.4556 of 5 stars		$13.07
-2.8%		$12.00
-8.2%		+178.0%$1.23BN/AN/A465
MNKD
MannKind
2.5859 of 5 stars		$3.80
-3.8%		$8.34
+119.6%		-33.7%$1.22B$348.97MN/A592
TYRA
Tyra Biosciences
2.9073 of 5 stars		$20.43
-2.8%		$46.89
+129.5%		+53.2%$1.22BN/AN/A87
TRAX
First Tracks Biotherapeutics
3.1048 of 5 stars		$33.28
-1.9%		$65.17
+95.8%		N/A$1.19BN/AN/A104

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners
Nvidia’s record quarter could send this new type of AI soaring
Nvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...
Brownstone Research | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
I've seen this movie before (last time: 17,556%)
My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...
Crypto 101 Media | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel